Skip to main content
Top
Published in: Tumor Biology 6/2015

Open Access 01-06-2015 | Research Article

Divergent expression patterns of SATB1 mRNA and SATB1 protein in colorectal cancer and normal tissues

Authors: Anna E. Kowalczyk, Janusz Godlewski, Bartlomiej E. Krazinski, Jolanta Kiewisz, Agnieszka Sliwinska-Jewsiewicka, Przemyslaw Kwiatkowski, Bartosz Pula, Piotr Dziegiel, Jacek Janiszewski, Piotr M. Wierzbicki, Zbigniew Kmiec

Published in: Tumor Biology | Issue 6/2015

Login to get access

Abstract

Special AT-rich sequence-binding protein 1 (SATB1) is a ‘genome organizer,’ and it has been proposed as a factor that affects the development and progression of various human neoplasms, including colorectal cancer (CRC). This study aimed to compare SATB1 expression in a group of CRC patients and healthy subjects at the mRNA and protein levels. We collected paired tumor tissue and unchanged mucosa of the large intestine from 102 CRC patients as well as 53 biopsies of normal colon mucosa obtained from healthy patients during screening colonoscopy. Tissue samples were quantified for SATB1 mRNA by quantitative PCR, while SATB1 protein expression was determined by Western blotting and immunohistochemistry. SATB1 mRNA level in tumor tissues was over twofolds lower than in samples of corresponding unchanged tissues and fourfolds lower than in biopsies of healthy colon mucosa. Western blotting analysis revealed that SATB1 protein content in tumor and unchanged tissues of CRC patients was over sixfold and fivefolds higher than in biopsies of healthy colon mucosa, respectively. Immunohistochemical staining demonstrated higher nuclear and cytoplasmic SATB1 reactivity in the tumor tissue compared to unchanged mucosa of CRC patients. Despite these differences, SATB1 mRNA, protein, and immunoreactivity levels did not correlate with patients’ clinicopathological data and their overall survival, but the latter analysis was limited by a relatively short period of follow-up. In conclusion, we suggest that some as yet unidentified posttranscriptional mechanisms that regulate SATB1 expression may be altered in the CRC tissue.
Literature
1.
go back to reference Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.CrossRefPubMed Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.CrossRefPubMed
2.
go back to reference Pavan Kumar P, Purbey PK, Sinha CK, Notani D, Limaye A, Jayani RS, et al. Phosphorylation of SATB1, a global gene regulator, acts as a molecular switch regulating its transcriptional activity in vivo. Mol Cell. 2006;22(2):231–43.CrossRefPubMed Pavan Kumar P, Purbey PK, Sinha CK, Notani D, Limaye A, Jayani RS, et al. Phosphorylation of SATB1, a global gene regulator, acts as a molecular switch regulating its transcriptional activity in vivo. Mol Cell. 2006;22(2):231–43.CrossRefPubMed
3.
go back to reference Han HJ, Russo J, Kohwi Y, Kohwi-Shigematsu T. SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature. 2008;452(7184):187–93.CrossRefPubMed Han HJ, Russo J, Kohwi Y, Kohwi-Shigematsu T. SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature. 2008;452(7184):187–93.CrossRefPubMed
4.
go back to reference Kobierzycki C, Wojnar A, Dziegiel P. Expression of SATB1 protein in the ductal breast carcinoma tissue microarrays—preliminary study. Folia Histochem Cytobiol. 2013;51(4):333–8.CrossRefPubMed Kobierzycki C, Wojnar A, Dziegiel P. Expression of SATB1 protein in the ductal breast carcinoma tissue microarrays—preliminary study. Folia Histochem Cytobiol. 2013;51(4):333–8.CrossRefPubMed
5.
go back to reference Zhao XD, Ji WY, Zhang W, He LX, Yang J, Liang HJ, et al. Overexpression of SATB1 in laryngeal squamous cell carcinoma. ORL J Otorhinolaryngol Relat Spec. 2010;72(1):1–5.CrossRefPubMed Zhao XD, Ji WY, Zhang W, He LX, Yang J, Liang HJ, et al. Overexpression of SATB1 in laryngeal squamous cell carcinoma. ORL J Otorhinolaryngol Relat Spec. 2010;72(1):1–5.CrossRefPubMed
6.
go back to reference Sun F, Lu X, Li H, Peng Z, Wu K, Wang G, et al. Special AT-rich sequence binding protein 1 regulates the multidrug resistance and invasion of human gastric cancer cells. Oncol Lett. 2012;4(1):156–62.PubMedPubMedCentral Sun F, Lu X, Li H, Peng Z, Wu K, Wang G, et al. Special AT-rich sequence binding protein 1 regulates the multidrug resistance and invasion of human gastric cancer cells. Oncol Lett. 2012;4(1):156–62.PubMedPubMedCentral
7.
go back to reference Tu W, Luo M, Wang Z, Yan W, Xia Y, Deng H, et al. Upregulation of SATB1 promotes tumor growth and metastasis in liver cancer. Liver Int. 2012;32(7):1064–78.CrossRefPubMed Tu W, Luo M, Wang Z, Yan W, Xia Y, Deng H, et al. Upregulation of SATB1 promotes tumor growth and metastasis in liver cancer. Liver Int. 2012;32(7):1064–78.CrossRefPubMed
8.
go back to reference Xiang J, Zhou L, Li S, Xi X, Zhang J, Wang Y, et al. AT-rich sequence binding protein 1: contribution to tumor progression and metastasis of human ovarian carcinoma. Oncol Lett. 2012;3(4):865–70.PubMedPubMedCentral Xiang J, Zhou L, Li S, Xi X, Zhang J, Wang Y, et al. AT-rich sequence binding protein 1: contribution to tumor progression and metastasis of human ovarian carcinoma. Oncol Lett. 2012;3(4):865–70.PubMedPubMedCentral
9.
go back to reference Li QQ, Chen ZQ, Xu JD, Cao XX, Chen Q, Liu XP, et al. Overexpression and involvement of special AT-rich sequence binding protein 1 in multidrug resistance in human breast carcinoma cells. Cancer Sci. 2010;101(1):80–6.CrossRefPubMed Li QQ, Chen ZQ, Xu JD, Cao XX, Chen Q, Liu XP, et al. Overexpression and involvement of special AT-rich sequence binding protein 1 in multidrug resistance in human breast carcinoma cells. Cancer Sci. 2010;101(1):80–6.CrossRefPubMed
10.
go back to reference Kohwi-Shigematsu T, Poterlowicz K, Ordinario E, Han HJ, Botchkarev VA, Kohwi Y. Genome organizing function of SATB1 in tumor progression. Semin Cancer Biol. 2013;23(2):72–9.CrossRefPubMed Kohwi-Shigematsu T, Poterlowicz K, Ordinario E, Han HJ, Botchkarev VA, Kohwi Y. Genome organizing function of SATB1 in tumor progression. Semin Cancer Biol. 2013;23(2):72–9.CrossRefPubMed
11.
go back to reference Iorns E, Hnatyszyn HJ, Seo P, Clarke J, Ward T, Lippman M. The role of SATB1 in breast cancer pathogenesis. J Natl Cancer Inst. 2010;102(16):1284–96.CrossRefPubMed Iorns E, Hnatyszyn HJ, Seo P, Clarke J, Ward T, Lippman M. The role of SATB1 in breast cancer pathogenesis. J Natl Cancer Inst. 2010;102(16):1284–96.CrossRefPubMed
12.
go back to reference Selinger CI, Cooper WA, Al-Sohaily S, Mladenova DN, Pangon L, Kennedy CW, et al. Loss of special AT-rich binding protein 1 expression is a marker of poor survival in lung cancer. J Thorac Oncol. 2011;6(7):1179–89.CrossRefPubMed Selinger CI, Cooper WA, Al-Sohaily S, Mladenova DN, Pangon L, Kennedy CW, et al. Loss of special AT-rich binding protein 1 expression is a marker of poor survival in lung cancer. J Thorac Oncol. 2011;6(7):1179–89.CrossRefPubMed
13.
go back to reference Zhou LY, Liu F, Tong J, Chen QQ, Zhang FW. Expression of special AT-rich sequence-binding protein mRNA and its clinicopathological significance in non-small cell lung cancer. Nan Fang Yi Ke Da Xue Xue Bao. 2009;29(3):534–7.PubMed Zhou LY, Liu F, Tong J, Chen QQ, Zhang FW. Expression of special AT-rich sequence-binding protein mRNA and its clinicopathological significance in non-small cell lung cancer. Nan Fang Yi Ke Da Xue Xue Bao. 2009;29(3):534–7.PubMed
14.
go back to reference Meng WJ, Yan H, Zhou B, Zhang W, Kong XH, Wang R, et al. Correlation of SATB1 overexpression with the progression of human rectal cancer. Int J Color Dis. 2012;27(2):143–50.CrossRef Meng WJ, Yan H, Zhou B, Zhang W, Kong XH, Wang R, et al. Correlation of SATB1 overexpression with the progression of human rectal cancer. Int J Color Dis. 2012;27(2):143–50.CrossRef
15.
go back to reference Nodin B, Johannesson H, Wangefjord S, O’Connor DP, Ericson-Lindquist K, Uhlén M, et al. Molecular correlates and prognostic significance of SATB1 expression in colorectal cancer. Diagn Pathol. 2012;7:115.CrossRefPubMedPubMedCentral Nodin B, Johannesson H, Wangefjord S, O’Connor DP, Ericson-Lindquist K, Uhlén M, et al. Molecular correlates and prognostic significance of SATB1 expression in colorectal cancer. Diagn Pathol. 2012;7:115.CrossRefPubMedPubMedCentral
16.
go back to reference Zhang J, Zhang B, Zhang X, Sun Y, Wei X, McNutt MA, et al. SATB1 expression is associated with biologic behavior in colorectal carcinoma in vitro and in vivo. PLoS One. 2013;8(1):e47902.CrossRefPubMedPubMedCentral Zhang J, Zhang B, Zhang X, Sun Y, Wei X, McNutt MA, et al. SATB1 expression is associated with biologic behavior in colorectal carcinoma in vitro and in vivo. PLoS One. 2013;8(1):e47902.CrossRefPubMedPubMedCentral
17.
go back to reference Fang XF, Hou ZB, Dai XZ, Chen C, Ge J, Shen H, et al. Special AT-rich sequence-binding protein 1 promotes cell growth and metastasis in colorectal cancer. World J Gastroenterol. 2013;19(15):2331–9.CrossRefPubMedPubMedCentral Fang XF, Hou ZB, Dai XZ, Chen C, Ge J, Shen H, et al. Special AT-rich sequence-binding protein 1 promotes cell growth and metastasis in colorectal cancer. World J Gastroenterol. 2013;19(15):2331–9.CrossRefPubMedPubMedCentral
18.
go back to reference Al-Sohaily S, Henderson C, Selinger C, Pangon L, Segelov E, Kohonen-Corish M, et al. Loss of special AT-rich sequence-binding protein 1 (SATB1) predicts poor survival in patients with colorectal cancer. Histopathology. 2014;65(2):155–63.CrossRefPubMed Al-Sohaily S, Henderson C, Selinger C, Pangon L, Segelov E, Kohonen-Corish M, et al. Loss of special AT-rich sequence-binding protein 1 (SATB1) predicts poor survival in patients with colorectal cancer. Histopathology. 2014;65(2):155–63.CrossRefPubMed
19.
go back to reference Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402–8.CrossRefPubMed Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402–8.CrossRefPubMed
20.
go back to reference Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–54.CrossRefPubMed Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–54.CrossRefPubMed
21.
go back to reference Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer. Pathologe. 1987;8:138–40.PubMed Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer. Pathologe. 1987;8:138–40.PubMed
22.
go back to reference Alvarez JD, Yasui DH, Niida H, Joh T, Loh DY, Kohwi-Shigematsu T. The MAR-binding protein SATB1 orchestrates temporal and spatial expression of multiple genes during T-cell development. Genes Dev. 2000;14(5):521–35.PubMedPubMedCentral Alvarez JD, Yasui DH, Niida H, Joh T, Loh DY, Kohwi-Shigematsu T. The MAR-binding protein SATB1 orchestrates temporal and spatial expression of multiple genes during T-cell development. Genes Dev. 2000;14(5):521–35.PubMedPubMedCentral
23.
go back to reference Li QQ, Chen ZQ, Cao XX, Xu JD, Xu JW, Chen YY, et al. Involvement of NF-κB/miR-448 regulatory feedback loop in chemotherapy-induced epithelial-mesenchymal transition of breast cancer cells. Cell Death Differ. 2011;18(1):16–25.CrossRefPubMed Li QQ, Chen ZQ, Cao XX, Xu JD, Xu JW, Chen YY, et al. Involvement of NF-κB/miR-448 regulatory feedback loop in chemotherapy-induced epithelial-mesenchymal transition of breast cancer cells. Cell Death Differ. 2011;18(1):16–25.CrossRefPubMed
24.
go back to reference McInnes N, Sadlon TJ, Brown CY, Pederson S, Beyer M, Schultze JL, et al. FOXP3 and FOXP3-regulated microRNAs suppress SATB1 in breast cancer cells. Oncogene. 2012;31(8):1045–54.CrossRefPubMed McInnes N, Sadlon TJ, Brown CY, Pederson S, Beyer M, Schultze JL, et al. FOXP3 and FOXP3-regulated microRNAs suppress SATB1 in breast cancer cells. Oncogene. 2012;31(8):1045–54.CrossRefPubMed
25.
go back to reference Lakshminarayana Reddy CN, Vyjayanti VN, Notani D, Galande S, Kotamraju S. Down-regulation of the global regulator SATB1 by statins in COLO205 colon cancer cells. Mol Med Rep. 2010;3(5):857–61.PubMed Lakshminarayana Reddy CN, Vyjayanti VN, Notani D, Galande S, Kotamraju S. Down-regulation of the global regulator SATB1 by statins in COLO205 colon cancer cells. Mol Med Rep. 2010;3(5):857–61.PubMed
26.
go back to reference Nakayama Y, Mian IS, Kohwi-Shigematsu T, Ogawa T. A nuclear targeting determinant for SATB1, a genome organizer in the T cell lineage. Cell Cycle. 2005;4(8):1099–106.CrossRefPubMed Nakayama Y, Mian IS, Kohwi-Shigematsu T, Ogawa T. A nuclear targeting determinant for SATB1, a genome organizer in the T cell lineage. Cell Cycle. 2005;4(8):1099–106.CrossRefPubMed
Metadata
Title
Divergent expression patterns of SATB1 mRNA and SATB1 protein in colorectal cancer and normal tissues
Authors
Anna E. Kowalczyk
Janusz Godlewski
Bartlomiej E. Krazinski
Jolanta Kiewisz
Agnieszka Sliwinska-Jewsiewicka
Przemyslaw Kwiatkowski
Bartosz Pula
Piotr Dziegiel
Jacek Janiszewski
Piotr M. Wierzbicki
Zbigniew Kmiec
Publication date
01-06-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 6/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3084-0

Other articles of this Issue 6/2015

Tumor Biology 6/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine